-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Assumes Candel Therapeutics at Buy, Announces Price Target of $23

Benzinga·06/30/2025 11:09:36
Listen to the news
HC Wainwright & Co. analyst Andrew Fein assumes Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $23.